T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.55% |
| 2 | Healthcare | 16.29% |
| 3 | Consumer Discretionary | 15.56% |
| 4 | Financials | 12.85% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1101
BridgeBio Pharma
BBIO
$15.9B
| $37.3M | ﹤0.01% |
605,990
+575,776
| +1,906% | +$37.7M |
|
1102
Main Street Capital
MAIN
$5.54B
| $37.3M | ﹤0.01% |
953,045
+76,669
| +9% | +$2.69M |
|
1103
iShares Core MSCI EAFE ETF
IEFA
$196B
| $37.3M | ﹤0.01% |
517,826
-2,669
| -0.5% | -$191K |
|
1104
Annexon
ANNX
$862M
| $37.3M | ﹤0.01% |
1,339,361
+133,858
| +11% | +$3.68M |
|
1105
Factset
FDS
$10.2B
| $37.2M | ﹤0.01% |
120,701
-32,801
| -21% | -$10.4M |
|
1106
Moog Inc Class A
MOG.A
$13.6B
| $37M | ﹤0.01% |
445,557
-175,199
| -28% | -$14M |
|
1107
Oneok
OKE
$58.3B
| $37M | ﹤0.01% |
731,268
-44,389
| -6% | -$2.02M |
|
1108
Synchrony
SYF
$26.1B
| $36.8M | ﹤0.01% |
904,370
-48,666
| -5% | -$1.88M |
|
1109
Frontdoor
FTDR
$5.83B
| $36.7M | ﹤0.01% |
683,253
-34,917
| -5% | -$1.9M |
|
|
CERN
1110
DELISTED
Cerner Corp
CERN
| $36.6M | ﹤0.01% |
509,635
-123,825
| -20% | -$9.3M |
|
1111
CorVel
CRVL
$3.25B
| $36.6M | ﹤0.01% |
1,070,262
-34,860
| -3% | -$1.21M |
|
1112
GoDaddy
GDDY
$12.7B
| $36.5M | ﹤0.01% |
470,041
+7,359
| +2% | +$592K |
|
|
PPL
1113
PPL Corp
PPL
$26.8B
| $36.4M | ﹤0.01% |
1,262,771
-104,039
| -8% | -$2.91M |
|
|
CDR
1114
DELISTED
Cedar Realty Trust, Inc
CDR
| $36.4M | ﹤0.01% |
2,442,479
+41,184
| +2% | +$535K |
|
1115
Kymera Therapeutics
KYMR
$9.51B
| $36.3M | ﹤0.01% |
932,978
+540,902
| +138% | +$32.6M |
|
|
LBPH
1116
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $36.2M | ﹤0.01% |
+2,302,749
| New | +$37.6M |
|
1117
Crown Holdings
CCK
$13.1B
| $36.1M | ﹤0.01% |
372,211
+4,034
| +1% | +$389K |
|
1118
Ziff Davis
ZD
$1.92B
| $36M | ﹤0.01% |
345,437
-63,851
| -16% | -$6.01M |
|
|
AAN
1119
DELISTED
The Aaron's Company Inc
AAN
| $35.8M | ﹤0.01% |
1,392,793
+591,858
| +74% | +$13M |
|
1120
Host Hotels & Resorts
HST
$15.6B
| $35.7M | ﹤0.01% |
2,120,432
-715,266
| -25% | -$11.2M |
|
1121
PDF Solutions
PDFS
$2.19B
| $35.7M | ﹤0.01% |
2,007,056
-293,727
| -13% | -$5.82M |
|
1122
Tapestry
TPR
$25.9B
| $35.7M | ﹤0.01% |
865,487
-13,253
| -2% | -$511K |
|
1123
Highwoods Properties
HIW
$3.51B
| $35.7M | ﹤0.01% |
830,424
+48,538
| +6% | +$1.98M |
|
1124
Hilton Grand Vacations
HGV
$3.49B
| $35.6M | ﹤0.01% |
949,149
-147,629
| -13% | -$5.31M |
|
1125
Douglas Dynamics
PLOW
$981M
| $35.6M | ﹤0.01% |
770,720
-61,913
| -7% | -$2.85M |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.